A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
Status:
Completed
Trial end date:
2017-12-29
Target enrollment:
Participant gender:
Summary
This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated
interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic
hepatitis D. Patients will be randomized to receive 96 weeks of therapy with Pegasys (180
micrograms sc weekly) plus either placebo (orally daily) or tenofovir (245mg orally daily).
Anticipated time on study treatment is 2+ years, target sample size is <50.